CurrentCignaPolicy N/A

Miglustat (Zavesca) prior authorization for Gaucher disease and Niemann-Pick C

This policy governs prior authorization and medical necessity criteria for miglustat capsules (Zavesca and generics) for treatment of Gaucher disease Type 1 and Niemann-Pick disease Type C for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyMiglustat (Zavesca) prior authorization for Gaucher disease and Niemann-Pick C

Policy CodePolicy N/A

Change TypeCriteria revised and new condition added

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document diagnostic confirmation (biallelic pathogenic variants for GBA or NPC1/NPC2, or enzyme assay for Gaucher) for approval up to 1 year.

SourceLink

POLICY UPDATE CHANGES

Confirmation by genetic testing language for Gaucher Disease Type 1 was rephrased to require genetic test showing biallelic pathogenic GBA variants.

Niemann-Pick Disease Type C was added as a new condition of approval with criteria requiring biallelic pathogenic NPC1 or NPC2 variants and age ≥2 years.

A requirement was added that miglustat not be used for management of neurological manifestations in Gaucher Disease Type 1.

Conditions Not Covered: Concomitant use with other approved therapies for Gaucher disease was added as not medically necessary.

2approved indications listed

1 yrstandard approval duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Miglustat (Zavesca)

Gaucher Disease Type 1 (FDA-approved)

Covered when ALL of the following are met for up to 1 year:

Gaucher Type 1 approval: A) Diagnosis established by ONE of the following: i) demonstration of deficient β-glucocerebrosidase activity in leukocytes or fibroblasts; OR ii) molecular genetic test showing biallelic pathogenic GBA (glucocerebrosidase) gene variants; AND B) The medication is not being used for the management of neurological manifestations (examples include abnormal ocular movement, auditory impairment, cognitive impairment, and seizures); AND C) The medication is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or a physician who specializes in the treatment of Gaucher disease or related disorders.

Approve for 1 year.

Niemann-Pick Disease Type C (Supportive evidence)

Covered when ALL of the following are met for up to 1 year:

Niemann-Pick C approval: A) Patient is ≥ 2 years of age; AND B) Diagnosis established by molecular genetic test showing biallelic pathogenic variants in either the NPC1 or NPC2 gene; AND C) The medication is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or a physician who specializes in the treatment of Niemann-Pick Disease Type C or related disorders.age >= 2 years

Approve for 1 year.

Genetic confirmation / diagnostic criteria for covered indications

Diagnostic confirmation required for covered indications:

Gaucher diagnostic confirmation: Diagnosis of Gaucher Disease Type 1 must be confirmed by ONE of: i) deficient β-glucocerebrosidase activity demonstrated in leukocytes or fibroblasts; OR ii) molecular genetic testing showing biallelic pathogenic variants in the GBA gene.biallelic

Niemann-Pick C diagnostic confirmation: Diagnosis of Niemann-Pick Disease Type C must be confirmed by molecular genetic testing showing biallelic pathogenic variants in either NPC1 or NPC2.biallelic

Concomitant administration of miglustat with other therapies approved for Gaucher disease is considered not medically necessary. The policy notes that published data supporting combined use are limited and inconsistent and explicitly lists examples of approved Gaucher therapies — including imiglucerase (Cerezyme), taliglucerase alfa (Elelyso), velaglucerase alfa (Vpriv), and eliglustat (Cerdelga) — to clarify the scope of this restriction.

Use of miglustat for any indication not expressly listed in this policy is considered not medically necessary. The policy labels Zavesca (miglustat capsules) as not medically necessary for “ANY other use(s),” and will be updated as new published data become available.

Covered Indications and Diagnostic Confirmation

Summary: required genetic or enzyme confirmation linked to covered indications

Covered indications require one of the following diagnostic confirmations and specialist prescribing:

Covered indication - Gaucher: Gaucher Disease Type 1 with diagnostic confirmation by either deficient β-glucocerebrosidase enzyme activity in leukocytes or fibroblasts OR molecular genetic testing showing biallelic pathogenic GBA variants.biallelic

Approvals are granted for 1 year and prior authorization is required.

Covered indication - NPC: Niemann-Pick Disease Type C with diagnostic confirmation by molecular genetic testing showing biallelic pathogenic variants in NPC1 or NPC2 (patient ≥ 2 years of age).biallelic; age >= 2 years

Approvals are granted for 1 year and prior authorization is required.

Eligibility Requirements

Eligibility for coverage of miglustat requires meeting the specific diagnostic and prescriber criteria for one of the policy’s covered indications. For Gaucher Disease Type 1, documentation must show either deficient β‑glucocerebrosidase activity in leukocytes or fibroblasts, or a molecular genetic test demonstrating biallelic pathogenic GBA variants; medication must not be used for management of neurological manifestations; and the drug must be prescribed by or in consultation with an appropriate specialist. For Niemann‑Pick Disease Type C (supportive evidence), the patient must be ≥ 2 years of age, have a molecular genetic test showing biallelic pathogenic NPC1 or NPC2 variants, and the prescription must be by or in consultation with an appropriate specialist. Requests that do not meet these diagnostic, age, or prescriber requirements are not eligible for approval.

Provider Actions and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required — prior authorization is required for miglustat capsules. Approvals are granted for 1 year when criteria are met.

Zavesca (miglustat capsules) prior authorization applies for FDA‑approved and supported indications.
Approvals issued for 12 months; renewal requires documentation that criteria continue to be met.

Denial Risk

Denial Risk for Noncompliant Claims

Denial Risk for Noncompliant Claims — Claims lacking a covered diagnosis or required supporting documentation may be denied as not covered.

Claims must include covered diagnosis/procedure codes aligned with the applicable benefit plan.
Documentation must include diagnostic confirmation (enzyme assay or genetic testing) and other records as required by the approval criteria.

Not Medically Necessary / Exclusions

Not covered: The policy explicitly states that concomitant use with other approved Gaucher disease therapies is not medically necessary. Additionally, any other uses of miglustat not specified in the policy are designated not medically necessary. This includes, but is not limited to, off‑label indications outside the two covered conditions described in the policy.

Definitions

Substrate reduction therapy (miglustat) — definition and term mapping

DefinitionMiglustat is a substrate reduction therapy that inhibits glycosylceramide synthase to reduce production of glucosylceramide, allowing residual β‑glucocerebrosidase activity to be more effective.

Mechanism of actionInhibits glycosylceramide synthase (glucosylceramide synthase), decreasing substrate (glucosylceramide) accumulation in lysosomes.

Primary FDA‑approved indicationMonotherapy for mild to moderate Type 1 Gaucher disease in adults when enzyme replacement therapy is not a therapeutic option (e.g., allergy, hypersensitivity, or poor venous access).

Other uses with supportive evidenceUsed off‑label for Niemann‑Pick disease Type C (NPC), an autosomal recessive disorder caused by pathogenic variants in NPC1 or NPC2.

Clinical rationaleBy reducing substrate synthesis, miglustat permits residual glucocerebrosidase to better clear accumulated glucosylceramide in visceral organs (liver, spleen, bone marrow).

Background

Gaucher disease is a rare autosomal recessive lysosomal storage disorder caused by deficient β‑glucocerebrosidase, leading to accumulation of glucosylceramide. Type 1 Gaucher disease is traditionally described as non‑neuronopathic, but neurological manifestations (for example, abnormal ocular movements, auditory impairment, cognitive impairment, and seizures) can occur and the policy specifies that miglustat should not be used for management of such neurological manifestations in Type 1. Miglustat is a substrate reduction therapy that inhibits glucosylceramide synthase and is an FDA‑approved oral treatment option for certain patients with Gaucher Disease Type 1; the policy also addresses its supportive use in Niemann‑Pick Disease Type C with distinct diagnostic and age criteria.